Clinical Trials Logo

Filter by:
NCT ID: NCT00778843 Completed - Chronic Hepatitis C Clinical Trials

Antioxidant and Immunomodulator Properties of Viusid in Patients With Chronic Hepatitis C

Start date: October 2008
Phase: Phase 3
Study type: Interventional

The pathogenesis of chronic hepatitis C (CHC) is associated to severe oxidative stress and non-selective immunological disturbance that leads to necro-inflammation and progression of fibrosis. Previous trials suggested that antioxidant and inmunostimulant therapies may have a beneficial effect. The purpose of the study is to evaluate whether Viusid, a nutritional supplement with hepatoprotective properties, could ameliorate the oxidative stress and modulate the immune response in patients with CHC and non-responders to pegylated interferon plus ribavirin, during 24 weeks of treatment.

NCT ID: NCT00712595 Completed - Uterine Fibroids Clinical Trials

Mifepristone for Treatment of Uterine Fibroids

Mifemyo
Start date: January 2007
Phase: Phase 2/Phase 3
Study type: Interventional

The objectives of this study are to estimate the efficacy and safety of the daily administration of mifepristone 5 mg versus 10 mg for three months for the treatment of uterine fibroids. The hypothesis of the study is that both mifepristone doses reduce the volume of the myoma in about 40% after 3 months of treatment.

NCT ID: NCT00509418 Completed - Clinical trials for Nonalcoholic Steatohepatitis

Efficacy and Safety of Viusid in Patients With Nonalcoholic Steatohepatitis

Start date: February 2007
Phase: Phase 3
Study type: Interventional

The purpose of the study is to evaluate whether Viusid, a nutritional supplement, in combination with diet and exercise improve the histological results (steatosis, necro-inflammatory activity and fibrosis) in comparison with diet and exercise, during 24 weeks of treatment.

NCT ID: NCT00502086 Completed - Cirrhosis Clinical Trials

Efficacy and Safety of Viusid in Patients With Hepatic Cirrhosis Secondary to Hepatitis C Virus Infection.

Start date: May 2005
Phase: Phase 3
Study type: Interventional

The purpose of the study is to evaluate whether Viusid, a nutritional supplement, reduce the mortality and the complications (ascites, spontaneous bacterial peritonitis, hepatorenal syndrome, hepatic encephalopathy, gastrointestinal bleeding, sepsis and hepatocellular carcinoma) of patients with cirrhosis of the liver secondary to HCV infection in comparison with placebo, during 96 weeks of treatment.